A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.
Ontology highlight
ABSTRACT: Transgenic expression of key myelosupportive human cytokines in immune-deficient mice corrects for the lack of cross-species activities of stem cell factor (SCF), IL-3, and GM-CSF. When engrafted with human umbilical cord blood (UCB), these triple-transgenic mice produce BM and spleen grafts with much higher myeloid composition, relative to nontransgenic controls. Shortly after engraftment with UCB, these mice develop a severe, fatal macrophage activation syndrome (MAS) characterized by a progressive drop in rbc numbers, increased reticulocyte counts, decreased rbc half-life, progressive cytopenias, and evidence of chronic inflammation, including elevated human IL-6. The BM becomes strikingly hypocellular, and spleens are significantly enlarged with evidence of extramedullary hematopoiesis
SUBMITTER: Wunderlich M
PROVIDER: S-EPMC5033750 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA